Ambrx breaks deal mold with Zhejiang ADC alliance
This article was originally published in Scrip
Executive Summary
Research-based alliances between Chinese and Western pharma/biotech partners have been on an upward arc over the past year, driven by the desire of smaller US and European companies to gain access to China's growing market and their Chinese counterparts' rising hunger for innovation.
You may also be interested in...
Cancer’s Next-Gen Smart Bomb: Who Will Be First To Weaponize?
With 70 clinical trials now underway on a “next generation” of more precisely targeted antibody drug conjugates, In Vivo profiles Ambrx and Sutro Biopharma, two smaller biotechs with promising technologies and powerful partners that augment their strong science with disease awareness, deep commercial networks and global geographic reach.
Santen Gains Ready-Made US Portfolio Via $225m Eyevance Buy
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
Asia Deal Watch: Cancer Collaborations, Licensings Lead Activity In Asia
Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.
Need a specific report? 1000+ reports available Buy Reports